Foghorn Therapeutics (FHTX) Stock Research

Foghorn Therapeutics

· FHTX

Dashboard

Financials

Ratios

Valuation

Statistics

153.41 M

-26.61%

Today

Foghorn Therapeutics downgraded at Citizens after FHD-909 discontinuation

3:00 PM

Citizens gets more bearish on Foghorn Therapeutics, downgrades shares

FHTX

2:45 PM

Foghorn Therapeutics price target lowered by $7 at Stifel, here's why

12:53 PM

Foghorn Therapeutics drops 44% after scrapping FHD-909 program

FHTX

9:03 AM

Foghorn, Lilly to not advance FHD-909 program, Foghorn to reduce workforce

7:07 AM

Over a week ago

Foghorn Therapeutics reports Q2 EPS (10c), consensus (23c)

FHTX

Aug 6, 7:24 AM

Foghorn Therapeutics reports Q1 EPS (29c), consensus (31c)

FHTX

May 7, 7:32 AM

Foghorn Therapeutics presents new preclinical data for FHD-909

FHTX

Apr 21, 4:14 PM

Foghorn Therapeutics appoints Maynard as Chief Financial Officer

FHTX

Feb 23, 7:05 AM

Foghorn Therapeutics price target lowered by $2 at Jefferies, here's why

FHTX

Feb 17, 6:16 AM

Foghorn Therapeutics initiated with bullish view at BTIG, here's why

FHTX

Dec 18, 6:53 AM

Foghorn Therapeutics initiated with a Buy at Stifel

Dec 3, 4:18 PM

Foghorn Therapeutics initiated with bullish view at Guggenheim

FHTX

Nov 7, 6:27 AM

Foghorn Therapeutics reports Q3 EPS (25c), consensus (30c)

FHTX

Nov 5, 7:02 AM

Foghorn announces updates for Selective ARID1B, Selective CBP, Selective EP300

FHTX

Oct 30, 7:37 AM

Foghorn Therapeutics announces progress for Selective ARID1B degrader program

FHTX

Oct 16, 7:08 AM

No more stories

Charts